
APIs Pipeline





Letermovir (CAS-RN 917389-32-3) is an antiviral agent approved in 2017 by US FDA to be used in prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). Designated an orphan drug by FDA for prevention of CMV viremia and disease in at-risk populations.

Main Therapeutic Application	ANTIVIRAL
CAS-RN	917389-32-3
Specification	In House
Documentation	Under Development



+34 93 377 00 51 lebsa@lebsa.com www.lebsa.com

MADE IN EUROPE

HEADQUARTERS: Ctra. de l'Hospitalet, 34 08940 Cornellà (Barcelona) SPAIN



For more information about our R&D pipeline and CDMO services

CONTACT US